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ABSTRACT
Recent years have witnessed a number of clinical trials in Stage IIIA non–small cell lung cancer (NSCLC) compar-
ing (A) induction chemotherapy (CHT) with induction CHT and radiotherapy (RT), each followed by surgery;
(B) either induction CHT or induction RT-CHT, each followed by surgery, with deﬁnitive RT-CHT (no surgery).
Due to the heterogeneity of patient, tumor and treatment characteristics across these trials, various meta-analyses
(MAs) have been performed to deﬁne the optimal treatment approach in this setting for this clinical presentation.
Six such MAs exist. In spite of the differences between MAs, it appears that RT does not add extra beneﬁt to
induction CHT administered before surgery, and that a trimodality (i.e. including surgery) regimen is not superior
to deﬁnitive concurrent RT-CHT. While one can consider both induction CHT followed by surgery and exclusive
concurrent RT-CHT as feasible in this setting, lack of pre-treatment predictive factors identifying patients who
might preferentially beneﬁt from a surgical approach limits its use to well-planned clinical trials.
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INTRODUCTION
Over the past three decades thoracic oncologists have intensively
debated the most appropriate treatment for patients with Stage IIIA
(typically as pN2) non–small cell lung cancer (NSCLC). A range of
combined modality approaches have been tested and tried for cure.
Surgery has been employed [preceded by induction chemotherapy
(CHT), with or without concurrent radiation therapy (RT)] in a
number of studies and it has shown promising results in this patient
population [1–8]. In patients treated without surgery, deﬁnitive
concurrent RT-CHT became the standard treatment approach for
inoperable Stage III NSCLC patients [9–11]. Recently, a number of
prospective randomized clinical trials (RCTs) compared various
induction regimens followed by surgery with deﬁnitive non-surgical
treatment. Notwithstanding the various study designs and eligibility
criteria in these RCTs, their ﬁndings were consistent: either concur-
rent RT-CHT or sequential CHT-RT without surgery is as effective
as either induction approach followed by surgery [12–18].
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In spite of this strong evidence for the lack of beneﬁt from the
addition of surgery, many thoracic surgeons and oncologists as well
as professional bodies [19, 20] continue to suggest that surgery is
indicated for some ‘appropriate’ patients with Stage IIIA disease,
although the deﬁnition of ‘appropriateness’ is variable. For example,
in one study [16] an unplanned post-hoc subgroup analysis sug-
gested a survival beneﬁt for surgery in lobectomy-suitable patients.
Given this controversy, a number of meta-analyses (MAs) have
been carried out to help in resolving the issue, looking at the differ-
ences between the patient and/or tumor and/or treatment charac-
teristics of these randomized studies. These MAs have addressed
two separate questions (Table 1):
(A) Which is the more effective induction treatment before
surgery: induction CHT alone or with RT?
(B) Which is the most effective overall curative approach:
induction CHT (with or without RT) followed by surgery,
or RT-CHT alone (no surgery)?
Our aim was to review the quality of the MAs with respect to
their content and their conclusions regarding the role of surgery in
Stage IIIA NSCLC.
MATERIAL AND METHODS
References were identiﬁed through a search of PubMed using the
terms ‘meta-analysis’, ‘systematic review’, ‘non–small cell lung cancer’,
‘surgery’, ‘radiotherapy’, ‘chemotherapy’ and ‘Stage IIIA’ for the interval
from 1990 until September 2016; through searches of the references of
the identiﬁed articles; and through searches of the authors’ own ﬁles.
The year 1990 was selected as the starting point for the survey as it
marks the contemporary era of RT delivery. Findings were restricted to
fully published English language articles.
Since our study was neither a MA nor a systematic review, but
rather an ‘ordinary’ review, we did not attempt any qualitative or
quantitative data synthesis. This was due to the extreme heterogeneity
in the subjects and therapies across both of the original studies
included in these analyses/reviews and, consequently, in their ﬁndings.
RESULTS
Meta-analyses addressing Question A
Addressing Question A (Table 2), Shah et al. [21] compared induc-
tion RT-CHT with induction CHT alone in patients with Stage
IIIA (N2) NSCLC who were to undergo surgery. They identiﬁed
seven studies, reporting on a total of 526 patients. Their study
included only one fully published RCT, two RCTs only in abstract
form, one Phase II randomized trial, and three retrospective reviews.
None of the studies showed a survival beneﬁt for induction RT-
CHT compared with induction CHT alone. The MAs performed
on two RCTs (one Phase III and one Phase II) (n = 156 patients)
demonstrated no beneﬁt in overall survival (OS) from adding RT
(HR 0.93; 95% CI 0.54–1.62; P = 0.81), nor did the MAs per-
formed on two out of three available retrospective studies (n = 183
patients, HR 0.77, 95% CI 0.50–1.19; P = 0.24). The inclusion of
retrospective papers, and data presented in abstract form only,
clearly limited the quality of this MA.
In the second of the MAs addressing Question A, Xu Y-P et al. [22]
analyzed seven RCTs involving 1049 patients. Their analysis con-
sisted of two parts (Table 2): the ﬁrst focused on Question A
(three RCTs, n = 229 patients), while the second focused on
Question B (four RCTs, n = 820 patients). Concerning Question
A, they found that although induction RT-CHT before surgical
resection led to a signiﬁcant increase in the rate of pathological
complete remission in resected mediastinal lymph nodes in Stage
IIIA (N2) NSCLC patients compared with those who received
induction CHT (HR 3.61; 95% CI 1.07–12.15; P = 0.04), there
was no signiﬁcant difference in tumor downstaging, OS (three trials),
(HR 0.79; 95% CI 0.57–1.09; P = 0.15) or progression-free survival
(PFS) (two trials) (HR 0.67; 95% CI 0.39–1.15; P = 0.15). This
Table 1. Questions in meta-analyses
Author (year) Question
Shah et al. [21] A. Which is the more effective induction treatment before surgery: CHT alone or RT-CHT?
Xu Y-P et al. [22] A. Which is the more effective induction treatment before surgery: CHT alone or RT-CHT?
B. Which is the most effective curative approach: induction CHT, with or without RT, followed by surgery,
or RT-CHT alone?
Ren et al. [25] B. Which is the most effective curative approach: induction CHT, with or without RT, followed by surgery,
or RT-CHT alone?
McElnay et al. [26] B. Which is the most effective curative approach: induction CHT, with or without RT, followed by surgery,
or RT-CHT alone?
Xu X-L et al. [27] B. Which is the most effective curative approach: induction CHT, with or without RT, followed by surgery,
or RT-CHT alone?
Guo SX et al. [24] A. Which is the more effective induction treatment before surgery: CHT alone or RT-CHT?
RT = radiotherapy; CHT = chemotherapy.
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Table 2. Meta-analyses—characteristics and ﬁndings
Author (year) Comparison N Type of studies Summary of ﬁndings Comment
Shah
et al. [21]
Induction CHT + surgery vs induction
RT-CHT + surgery
7 RCT (one full)
RCT (two abstracts)
Phase II (one full)
Retrospective (three full)
HR 0.93; 95% CI 0.54–1.62; P = 0.81 (for two RCTs;
n = 165)
HR 0.77, 95% CI 0.50–1.19; P = 0.24 (for two retrospective
studies; n = 183)
• No beneﬁt of adding RT to induction CHT
• Included retrospective studies and abstracts
Xu Y-P
et al. [22]
Induction CHT + surgery vs induction
RT-CHT + surgery
3 RCT (N = 229) OS (3 trials); HR 0.79; 95% CI 0.57–1.09; P = 0.15
PFS (2 trials), HR 0.67; 95% CI 0.39–1.15; P = 0.15
• No beneﬁt of adding RT to induction CHT
• No superiority of trimodality Tx over
concurrent RT-CHT in both OS and PFS
Induction CHT +/- RT + surgery vs
concurrent or sequential RT-CHT
4 RCT (N = 820) OS (4 trials), HR 0.95; 95% CI 0.81–1.10; P = 0.49
PFS (2 trials), HR 0.90; 95% CI 0.77–1.05; P = 0.19
Ren
et al. [25]
Induction CHT ± RT + surgery vs
concurrent RT-CHT
3 RCT (N = 1,048) 2-year OS: HR 1.00; 95% CI 0.85–1.17; P = 0.98
4-year OS: HR 1.13; 95% CI 0.85–1.51; P = 0.39
3-year PFS: HR 1.05; 95% CI 0.61–1.81; P = 0.86
• No superiority of trimodality Tx over
concurrent RT-CHT in both OS and PFS
McElnay
et al. [26]
Bimodality approach (CHT+surgery)
vs concurrent RT-CHT
4 RCT (N = 229) (bimodality
trials)
HR 1.01; 95% CI 0.82–1.23; P = 0.954 • No superiority of either bimodality or
trimodality Tx over concurrent RT-CHT
Trimodality approach (RT-CHT
+surgery) vs concurrent RT-CHT
2 RCT (N = 820) (trimodality
trials)
HR 0.87; 95% CI 0.75–1.01; P = 0.068
6 RCT (N = 1049) (all trials
combined)
HR 0.92; 95% CI 0.81–1.03; P = 0.157
Xu X-L
et al. [27]
Induction CHT ± RT + surgery vs
concurrent
RT-CHT
5 RCT only (n = 851) HR 0.94; 95% CI 0.81–1.09; P = 0.686 • No difference in OS in RCTs
• OS superior with surgical approach in
retrospective studies
• Pooled studies suggest superiority in OS of
surgical approach
• No difference in PFS
• Retrospective studies disproportionate
weighting
4 Retrospective only
(n = 11 154)
HR 0.58; 95% CI 0.46–0.71; P = 0.008
9 Pooled studies (n = 12 005) HR 0.70; 95% CI 0.56–0.87; P = 0.000
Guo SX
et al. [24]
Induction CHT + surgery vs induction
RT-CHT + surgery
12 Phase III RCT (three)
Phase II (one)
Retrospective (six)
Abstracts (two)
(total n = 2724)
HR 0.75; 95% CI 0.63–0.89; P = 0.001 (tumor
downstaging) (n = 6)
HR 0.72; 95% CI 0.60–0.88; P = 0.001 (pCR) (n = 6)
HR 0.64; 95% CI 0.48–0.85; P = 0.002 (local control)
(n = 5)
HR 0.89; 95% CI 0.68–1.19; P = 0.44 (5-year OS) (n = 4)
HR 0.74; 95% CI 0.43–1.26; P = 0.26 (5-year PFS) (n = 4)
HR 0.77; 95% CI 0.50–1.18; P = 0.24 (5-year OS) (n = 2)
HR 0.73; 95% CI 0.51–1.07; P = 0.20 (5-year PFS) (n = 2)
• Difference favoring induction RT-CHT in
tumor downstaging, pCR and local control,
but not OS or PFS
• Different N studies used for different
endpoints
RCT = randomized controlled trial; HR = hazard ratio; CI = conﬁdence interval; RT = radiation therapy; CHT = chemotherapy; OS = curative survival; PFS = progression-free survival; Tx = treatment; MA = meta-analysis; pCR = pathological complete
response in mediastinal lymph nodes.
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higher quality MA because of its use of RCTs only produced a
result identical to that of Shah et al. [21]. A recent prospective
RCT [23] not included in either MA showed that the addition of
induction RT to CHT did not improve outcomes; thus, it con-
ﬁrmed these MAs.
Most recently, Guo et al. [24] reported on the third MA addres-
sing Question A. They initially included twelve studies, with a total
of 2724 patients. Of these, there were three RCTs, one Phase II
study, six retrospective studies and two studies not fully published
(abstracts only). However, the lack of a complete set of data con-
cerning all end points used led to four studies being discarded. Of a
potential eight studies, six were used for investigating tumor down-
staging and pathological mediastinal lymph node complete response
(pCR), while ﬁve were used for assessing local control. In these
three separate analyses, induction RT-CHT was found to be super-
ior to induction CHT, both followed by surgery (HRs 0.75, 0.72
and 0.64, respectively). Four studies identiﬁed as PRCTs were actu-
ally three—the fourth one was a retrospective analysis of a
National Cancer Database in the USA; hence, it was a retrospective
one. Nevertheless, no difference in either OS (four studies: HR
0.89) or PFS (three studies: HR 0.74) was found. The same was
observed when two additional retrospective studies were exam-
ined separately (OS: HR 0.77; PFS: HR 0.73).
Meta-analyses addressing Question B
Three recent MAs have investigated whether induction with either
CHT or RT-CHT, followed by surgery, is more effective than RT-
CHT alone (no surgery) (Table 2). In the second component of
the aforementioned MA of Xu Y-P et al. [22], the authors found
that there was no signiﬁcant difference in OS or PFS in patients
who received induction CHT or RT-CHT prior to surgery com-
pared with those who received either sequential or concurrent RT-
CHT without surgery (HR 0.95; 95% CI 0.81–1.10; P = 0.49).
In a recent MA, Ren et al. [25] selected three RCT studies with
1048 patients and showed no difference in 2-year OS (HR 1.00;
95% CI 0.85–1.17; P = 0.98), 4-year OS (HR 1.13; 95% CI
0.85–1.51; P = 0.39) or 3-year PFS (HR 1.05; 95% CI 0.61–1.81;
P = 0.86) between the two approaches. These ﬁndings, though
clear, did not prevent these authors from speculating that adding
RT to induction CHT might improve PFS results in a multimodal-
ity setting (based on the ﬁndings of a single study, which was actu-
ally an unplanned, post-hoc subgroup analysis [16]).
In another recent MA, McElnay et al. [26] identiﬁed six relevant
trials [12–16, 18] and separated them into bimodality (CHT fol-
lowed by surgery) and trimodality (RT-CHT followed by surgery)
groups. The results of both bimodality and trimodality trials were
the same: there was no statistically signiﬁcant difference in OS
when either of the two were compared with RT-CHT alone; this
was also conﬁrmed when the data of all studies were pooled.
Although the authors acknowledged the lack of statistical signiﬁ-
cance, they could not refrain from suggesting a potential beneﬁt
from surgery (HR 0.87; 95% CI 0.75–1.01; P = 0.068) in the trials
of trimodality (RT-CHT followed by surgery), saying that there was
‘a distinct possibility of 13% relative improvement in OS’. It is not
clear what a 13% difference in HR actually means in terms of ‘rela-
tive’ or ‘absolute’ survival; their further speculation that patients
who receive surgery as part of trimodality treatment are likely to
have an OS better than from deﬁnitive RT-CHT was tendentious
since this has not been supported prospective RCTs.
Finally, the MA of Xu X-L et al. [27] included ﬁve RCTs
(n = 851) and four retrospective studies (n = 11 154). When the
analysis was conﬁned to the prospective RCTs, no difference was
found in OS (HR 0.94; 95% CI 0.81–1.09; P = 0.686) between
various induction (CHT alone or RT-CHT) regimens followed by
surgery and combined RT-CHT without surgery (mostly concur-
rent RT-CHT). In contrast, when this analysis was applied to the
retrospective group of studies, a surgical approach showed superior-
ity with respect to OS (HR 0.58; 95% CI 0.46–0.71; P = 0.008).
Also, when the datasets were pooled, the signiﬁcant difference favor-
ing the surgical approach remained (HR 0.70; 95% CI 0.56–0.87;
P = 0.000). Interestingly, and in contrast to the ﬁndings of
INT0139 [16], when PFS was used as an end point, this MA
showed no difference between surgical and non-surgical approaches
for this end point (HR 0.91; 95% CI 0.78–1.06). A major critique
of this MA is the inclusion of retrospective studies (with a range of
HRs, from 0.45 to 0.77), in particular that of Koshy et al. [28],
which had a disproportionate impact because of the thousands of
patients included in its analysis. The Koshy study [28] is concerning
due to the nature of its patient source (i.e. the National Cancer
Database in the USA—a hospital-based registry), since it cannot
control for multiple confounders such as the types of chemotherapy
administered, whether there was pre-treatment pathologic proof of
clinical N2 disease, the extent of mediastinal nodal involvement
(bulky versus non-bulky), the number of mediastinal nodal stations
involved, the use of positron emission tomography scans for staging,
patient performance status, total radiotherapy dosage employed,
overall treatment time, fractionation size, or radiotherapy treatment
technique. In addition, the majority of the population in this study
consisted of patients who underwent concurrent RT-CHT and had
inoperable disease, which is associated with a worse prognosis.
DISCUSSION
A MA is considered the highest level of evidence in ‘evidence-based’
oncology. It has frequently been used as the tool for either support-
ing existing standards or establishing new ones. Rigorous criteria are
used in all aspects of its design and execution. Its outcome should
then lead to unambiguous interpretation. It goes without saying that
the ‘quality’ of its ﬁndings depend on the quality of the source data
itself.
It is obvious from this review that these six MAs show different
levels of compliance with the standard set above. Most concerning are
those who include retrospective studies, abstract data from unpublished
series, or data from cancer databases that cannot provide important
patient and/or tumor and/or treatment characteristics. Importantly,
none of these MAs used individual patient data. It is, therefore, not sur-
prising that results may vary between some of the MAs.
One of the major concerns with all the MAs is that they did not
provide pooled data on treatment-related toxicities, in particular
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Grade 5 toxicities (treatment-related deaths), although Xu Y-P et al. [22]
listed this outcome for each trial. Previous RCTs had suggested
that mortality is usually four to ﬁve times higher in the surgical
arms [14–16], and may be as high as 26% if a right pneumonectomy
follows induction RT-CHT [16]. It can also be higher when a 90-day,
not just a 30-day, measure of post-operative mortality is taken into
account [29]. This is important since more recent studies show
reduced Grade 5 and lower toxicity being associated with induc-
tion regimens followed by surgery, which is to be compared with
the lower toxicity achieved in modern deﬁnitive concurrent RT-CHT
regimens.
CONCLUSIONS
Whatever the limitations of these MAs, it is feasible to draw some
conclusions about treatment approaches for Stage III lung cancer.
Regarding Question A on the preferred form of induction treatment
(CHT or RT-CHT), the consensus appears to be that there is no
signiﬁcant difference between CHT alone or RT-CHT when both
are followed by surgery. Regarding Question B, the general conclu-
sion would be that there is no additional beneﬁt from the addition
of surgery in the management of Stage III NSCLC. Perhaps most
striking is the difﬁculty the authors have of accepting the validity of
their own conclusions when it comes to the role for surgery in
Stage IIIA NSCLC. Witness the fact that some authors used ‘spe-
ciﬁc interpretation’ of their ﬁndings to speculate as to potential ben-
eﬁts from surgery, when none appear to exist. One should perhaps
then turn to the simple question thoracic oncologists seem to be
posing when ﬁrst seeing a Stage III NSCLC patient: what makes
this particular patient suitable for induction CHT or induction RT-
CHT, followed by surgery? Which patient characteristics and/or
tumor characteristic(s) can one use to claim that in this particular
situation, with one or more of these characteristics, a surgical
approach would be preferred over a non-surgical one? Which factor(s)
(in which combinations) could predict that a surgical approach is pref-
erable over a non-surgical one?
Unfortunately, our recent investigation of potential predictors of
surgical superiority over non-surgical ones has not disclosed a single
predictive pre-treatment patient- and/or tumor-related factor [30].
Furthermore, no single prospective RCT has evaluated this. Hence,
in the absence of predictive factors before treatment, we are unable
to identify patients who could preferentially beneﬁt from surgery.
Until the time we can identify, test and prove one or more possible
predictive factors, surgery should not be used as a standard treat-
ment approach outside a well-planned clinical trial.
ACKNOWLEDGEMENTS
All authors contributed to the following: (i) conception and design,
(ii) administrative support, (iii) provision of study materials (litera-
ture), (iv) collection and assembly of data, (v) data analysis and
interpretation, (vi) manuscript writing and (vii) ﬁnal approval of
manuscript.
CONFLICT OF INTEREST
The authors declare that there are no conﬂicts of interest.
REFERENCES
1. Pass HI, Pogrebniak HW, Steinberg SM et al. Randomized trial
of neoadjuvant therapy for lung cancer: interim analysis. Ann
Thorac Surg 1992;53:992–8.
2. Rosell R, Gomez-Codina J, Camps C et al. A randomized trial
comparing preoperative chemotherapy plus surgery with surgery
alone in patients with non-small-cell lung cancer. N Engl J Med
1994;330:153–8.
3. Roth JA, Fossella F, Komaki R et al. A randomized trial compar-
ing perioperative chemotherapy and surgery with surgery alone
in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer
Inst 1994;86:673–80.
4. Nagai K, Tsuchiya R, Mori T et al. A randomized trial compar-
ing induction chemotherapy followed by surgery with surgery
alone for patients with stage IIIA N2 non-small cell lung cancer
(JCOG 9209). J Thorac Cardiovasc Surg 2003;125:254–60.
5. Thomas M, Rübe C, Hoffknecht P et al. Effect of preoperative
chemoradiation in addition to preoperative chemotherapy: a
randomised trial in stage III non-small-cell lung cancer. Lancet
Oncol 2008;9:636–8.
6. Caglar HB, Baldini EH, Othus M et al. Outcomes of patients
with Stage III nonsmall cell lung cancer treated with chemother-
apy and radiation with and without surgery. Cancer 2009;115:
4156–66.
7. Cyjon A, Nili M, Fink F et al. Advanced non-small cell lung
cancer: induction chemotherapy and chemoradiation before
operation. Ann Thorac Surg 2002;74:342–7.
8. Gómez-Caro A, Boada M, Reguart N et al. Sleeve lobectomy
after induction chemoradiotherapy. Eur J Cardiothorac Surg
2012;41:1052–58.
9. Aupérin A, Le Péchoux C, Rolland E et al. Meta-analysis of con-
comitant versus sequential radiochemotherapy in locally
advanced non-small-cell lung cancer. J Clin Oncol 2010;28:
2181–90.
10. Liang H-Y, Zhou H, Li H-L et al. Chemo-radiotherapy for
advanced non-small cell lung cancer: concurrent or sequential?
It’s no longer the question: a systematic review. Int J Cancer
2010;127:718–28.
11. O’Rourke N, Roqué I Figuls M et al. Concurrent chemora-
diotherapy in non-small cell lung cancer. Cochrane Database Syst
Rev 2010;CD002140.
12. Shepherd FA, Johnston MR, Payne D et al. Randomized study of
chemotherapy and surgery versus radiotherapy for stage IIIA
non-small-cell lung cancer: a National Cancer Institute of Canada
Clinical Trials Group Study. Br J Cancer 1998;78:683–5.
13. Johnstone DW, Byhardt RW, Ettinger D et al. Phase III study
comparing chemotherapy and radiotherapy with preoperative
chemotherapy and surgical resection in patients with non-
small-cell lung cancer with spread to mediastinal lymph
nodes (N2); ﬁnal report of RTOG 89–01. Radiation Therapy
Oncology Group. Int J Radiat Oncol Biol Phys 2002;54:
365–9.
14. Stephens RJ, Girling DJ, Hopwood P et al. A randomised con-
trolled trial of pre-operative chemotherapy followed, if feasible,
by resection versus radiotherapy in patients with inoperable
Optimal therapy in Stage IIIA NSCLC • 271
Downloaded from https://academic.oup.com/jrr/article-abstract/58/3/267/3051915
by Universitätsbibliothek Bern user
on 23 February 2018
stage T3, N1, M0 or T1–3, N2, M0 non-small cell lung cancer.
Lung Cancer 2005;49:395–400.
15. van Meerbeeck JP, Kramer GW, van Schil PE et al. Randomized
controlled trial of resection versus radiotherapy after induction
chemotherapy in stage IIIA–N2 non-small-cell lung cancer.
J Natl Cancer Inst 2007;99:442–50.
16. Albain KS, Swann RS, Rusch VW et al. Radiotherapy plus
chemotherapy with or without surgical resection for stage III
non-small-cell lung cancer: a phase III randomised controlled
trial. Lancet 2009;374:379–86.
17. Sorensen JB, Riska H, Ravn et al. Scandinavian phase III trial of
neoadjuvant chemotherapy in NSCLC stages IB–IIIA/T3.
J Clin Oncol 2005;23:7146.
18. Eberhardt WE, Pöttgen C, Gauler TC et al. Phase III study of
surgery versus deﬁnitive concurrent chemoradiotherapy boost in
patients with resectable Stage IIIA(N2) and selected IIIB non-
small-cell lung cancer after induction chemotherapy and concur-
rent chemoradiotherapy (ESPATUE). J Clin Oncol 2015;33:
4194–201.
19. Willers H, Stinchcombe TE, Barriger RB et al. ACR appropri-
ateness criteria induction and adjuvant therapy for N2 non–
small-cell lung cancer. Am J Clin Oncol 2015;8:197–205.
20. Bezjak A, Temin S, Franklin G et al. Deﬁnitive and adjuvant
radiotherapy in locally advanced non-small-cell lung cancer:
American Society of Clinical Oncology clinical practice guideline
endorsement of the American Society for Radiation Oncology
evidence-based clinical practice guideline. J Clin Oncol 2015;33:
2100–05.
21. Shah AA, Berry MF, Tzao C et al. Induction chemoradiation is
not superior to induction chemotherapy alone in stage IIIA
lung cancer. Ann Thorac Surg 2012;93:1807–12.
22. Xu Y-P, Li B, Xu X-L et al. Is there a survival beneﬁt in patients
with Stage IIIA (N2) non-small cell lung cancer receiving
neoadjuvant chemotherapy and/or radiotherapy prior to
surgical resection. A systematic review and meta-analysis.
Medicine (Baltimore) 2015;94:e879.
23. Pless P, Stupp R, Ris H-B et al. Induction chemoradiation in
stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised
trial. Lancet 2015;386:1049–56.
24. Guo SX, Jian Y, Chen YL et al. Neoadjuvant chemoradiotherapy
vesus chemotherapy alone followed by surgery for resectable
Stage III non-small-cell lung cancer: a meta-analysis. Sci Rep
2016;6:34388.
25. Ren Z, Zhou S, Liu Z et al. Randomized controlled trials of
induction treatment and surgery versus combined chemother-
apy and radiotherapy in stages IIIA–N2 NSCLC: a systematic
review and meta-analysis. J Thorac Dis 2015;7:1414–22
26. McElnay PJ, Choong A, Jordan E et al. Outcome of surgery ver-
sus radiotherapy after induction treatment in patients with N2
disease: systematic review and meta-analysis of randomised
trials. Thorax 2015;70:764–8.
27. Xu X-L, Dan L, Chen W et al. Neoadjuvant chemoradiotherapy
or chemotherapy followed by surgery is superior to that fol-
lowed by deﬁnitive chemoradiation or radiotherapy in stage
IIIA(N2) nonsmall-cell lung cancer: a meta-analysis and system
review. OncoTargets Ther 2016;9:845–53.
28. Koshy M, Fedewa SA, Malik R et al. Improved survival asso-
ciated with neoadjuvant chemoradiation in patients with clinical
stage IIIA(N2) non-small-cell lung cancer. J Thorac Oncol 2013;
8:915–22.
29. Kim AW, Boffa DJ, Wang Z et al. An analysis, systematic
review, and meta analysis of the perioperative mortality after
neoadjuvant therapy and pneumonectomy for non-small cell
lung cancer. J Thorac Cardiovasc Surg 2012;143:55–63.
30. Jeremic B, Casas F, Dubinsky P et al. Surgery in Stage IIIA non-
small cell lung cancer: lack of predictive and prognostic factors
identifying any patient subgroup beneﬁting from it. Clin Lung
Cancer 2016;17:107–12.
272 • B. Jeremic et al.
Downloaded from https://academic.oup.com/jrr/article-abstract/58/3/267/3051915
by Universitätsbibliothek Bern user
on 23 February 2018
